Oncolytic virus for expression of immune checkpoint modulators
AssigneeTransgene S.A.
InventorsNathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
Life of this patent
Estimating the term…
Abstract
The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
Claims15
A method for treating a proliferative disease, comprising administering an oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s) wherein said virus is a vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in only the viral 14L gene and defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene, wherein said one or more immune checkpoint modulator(s) is an antibody that specifically binds to PD-1 or a pharmaceutical composition comprising an effective amount of said oncolytic virus wherein said virus is a vaccinia virus defective for Ribonucleotide reductase (RR) activity resulting from inactivating mutations in only the viral 14L gene and defective for thymidine kinase (TK) resulting from inactivating mutations in the J2R viral gene, wherein said one or more immune checkpoint modulator(s) is an antibody that specifically binds to PD-1 and a pharmaceutical acceptable vehicle.
Dependencies are inferred from the claim text.